JAZZ News Alert Jazz Pharmaceuticals (JAZZ) 165.33 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Jazz Pharmaceuticals (JAZZ) 165.33 $JAZZ

J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
at The Street - Mon Dec 22, 7:23AM CST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
VRX: 140.33 (-0.22), BMRN: 88.18 (+0.89), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), BMY: 59.15 (-0.01)

Top Pharmaceutical Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 20, 8:05AM CST
Source: Flickr user stockmonkeys.com. It has been tough lately for big pharmaceutical stocks to overcome the headwinds tied to patent expiration on some of the world's best-selling medicines. As a result, pharmaceutical stocks haven't been as...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), JAZZ: 165.33 (+1.83)

Top 5 IBD 50 Stalwarts, Newcomers In Turbulent Year
at Investor's Business Daily - Sat Dec 20, 7:02AM CST
The IBD 50 list of top-rated stocks identifies new market leaders as well as veterans that continue to outperform the market. A comparison of stocks on the current IBD 50 vs. the list from a year ago pinpoints four stocks -- Facebook, Noah Holdings,...
NOAH: 20.44 (-1.00), SAVE: 75.68 (+1.52), FB: 80.77 (+0.16), JAZZ: 165.33 (+1.83), GOOG: 528.77 (-1.82), BITA: 72.57 (+0.36), UAL: 64.93 (+2.45)

Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze(R) (asparaginase Erwinia chrysanthemi)
PR Newswire Europe - Fri Dec 19, 6:05PM CST
-- Expanded U.S. Labeling Offers an Alternative Method to Administer Erwinaze to Patients with ALL
JAZZ: 165.33 (+1.83)

Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)
PR Newswire - Fri Dec 19, 6:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase1.
JAZZ: 165.33 (+1.83)

Flamel progresses on single dose narcolepsy treatment
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:13PM CST

FLML: 17.01 (-0.98), JAZZ: 165.33 (+1.83)

How To Invest: Taking Stock Tips Can Mean Disaster
at Investor's Business Daily - Mon Dec 15, 4:58PM CST
To be a successful investor, it's very important to make decisions based on your own research and analysis. You have to stand on your own two feet. One recipe for disaster is to accept stock tips, be they from TV commentators or friends. Even if the...
JAZZ: 165.33 (+1.83)

Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 4:50PM CST
Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
BIIB: 340.89 (+5.13), JAZZ: 165.33 (+1.83), AMGN: 160.67 (+3.15), AFFX: 9.80 (+0.05)

Stocks Close Near Session Lows And Down For The Week
at Investor's Business Daily - Fri Dec 12, 3:33PM CST
Stocks closed lower Friday and near their lows for the day with the S&P 500 and the Dow Jones industrial average having their first down week in the past eight. For the Nasdaq, it was the second straight down week. In the stock market today, the...
ZUMZ: 37.53 (-0.31), CALM: 42.45 (-1.73), JAZZ: 165.33 (+1.83), CAR: 64.23 (-0.25), URI: 104.84 (+0.16)

Jazz kicks off Fast Track review process for VOD med
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 12:28PM CST

JAZZ: 165.33 (+1.83)

Stocks Down In Afternoon; Caterpillar, Joy Global Hit
at Investor's Business Daily - Fri Dec 12, 12:28PM CST
Stocks remained in negative territory early Friday afternoon as weak Chinese manufacturing data and falling oil prices fanned concerns of a global economic slowdown. The Dow Jones industrial average lost 1%, the S&P 500 fell 0.6% and the Nasdaq...
CNC: 105.96 (+1.03), JOY: 48.23 (+0.31), JAZZ: 165.33 (+1.83), CAT: 93.72 (+0.22), URI: 104.84 (+0.16)

Insider Trading Alert - JAZZ, ARE And SCLN Traded By Insiders
at The Street - Fri Dec 12, 10:30AM CST
Stocks with insider trader activity include JAZZ, ARE and SCLN
ARE: 89.23 (-0.23), JAZZ: 165.33 (+1.83), SCLN: 8.64 (+0.16)

Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease
PR Newswire Europe - Thu Dec 11, 3:05PM CST
-- Expects to complete submission in the first half of 2015
JAZZ: 165.33 (+1.83)

JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:39PM CST
Jazz Pharmaceuticals (JAZZ) shares slipped after announcing that JZP-386 was not administered in the first phase I study due to a technical dosing issue.
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), JAZZ: 165.33 (+1.83), CNCE: 11.76 (+0.11)

Look for Shares of Jazz Pharmaceuticals to Potentially Rebound after Yesterday's 2.64% Sell Off
Comtex SmarTrend(R) - Tue Dec 09, 4:21PM CST
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $172.65 to a high of $179.87. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $177.10 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 165.33 (+1.83)

Stock Market Today: Wall Street Drops; Conn's Down 40%
at Investor's Business Daily - Tue Dec 09, 10:55AM CST
Stocks were sharply lower in heavy volume at midday Tuesday, as falling oil prices prompted fears of a global economic slowdown. The Dow Jones industrial average was down 0.9%, the S&P 500 lost 0.8% and the Nasdaq slipped 0.6%. Volume was running...
CAVM: 62.46 (+0.43), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), JAZZ: 165.33 (+1.83), CONN: 18.23 (+1.23)

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Business Wire - Tue Dec 09, 7:30AM CST
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.
JAZZ: 165.33 (+1.83), CNCE: 11.76 (+0.11)

Top Global Stocks: Jazz, Actavis In IBD's World List
at Investor's Business Daily - Mon Dec 08, 5:39PM CST
Three top-ranked drugmakers are among IBD's 10 leading global growth stocks. One is in buying range. Jazz Pharmaceuticals (JAZZ) appears to have gained some traction after a disappointing breakout Nov. 5, when the stock cleared its buy point only to...
MNK: 97.84 (-0.29), JNJ: 104.59 (+0.31), ACT: 254.20 (-1.68), COV: 103.35 (+0.57), JAZZ: 165.33 (+1.83)

Stocks Sink In Late Trading: Tesla, McDonald's Dive
at Investor's Business Daily - Mon Dec 08, 2:06PM CST
Stocks stretched losses heading into the final hour of trading Monday. In the stock market today the Nasdaq fell 0.9%, the S&P 500 dropped 0.7%, and the Dow trimmed 0.6%. Volume was tracking higher across the board compared with Friday's levels. From...
TSLA: 222.26 (+1.29), AKRX: 36.47 (+0.43), UTX: 116.91 (-0.30), JAZZ: 165.33 (+1.83), MCD: 93.83 (-0.39), CELG: 109.60 (+3.48)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 22

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading

Top 5 Most Recently Viewed Articles

Gate Ventures Backs Japanese Web3 Gaming Innovator double jump.tokyo

Updated Category News Views 276

Gate Ventures Invests in double jump.tokyo Gate Ventures is making a significant impact in the blockchain and gaming sectors with its latest investment in double jump.tokyo Inc., a prominent player in Web3 gaming based in Japan. This strategic investment is part of a larger $10 million funding round led by SBI Investment. This backing represents more than just financial...

Continue Reading
Insights from Gridwise's Gig Mobility Report Highlight Trends

Updated Category News Views 1754

Gridwise Annual Gig Mobility Report Highlights The gig mobility industry is encountering significant challenges as economic conditions evolve. Consumers are feeling the pinch from rising prices, leading to resistance against fare increases. Moreover, driver wages are stagnating, which is causing utilization rates to remain low. As platforms strive for profitability, this...

Continue Reading
Esquire Financial Achieves Historic Stock Surge to $81.89

Updated Category News Views 124

Esquire Financial's Stock Reaches New Heights Esquire Financial Holdings Inc (NASDAQ: ESQ) has celebrated a remarkable achievement as its stock price reached an all-time high of $81.89 recently. This milestone reflects the company's strong financial health and market position, boasting a market capitalization of approximately $638 million. The surge in price signals a...

Continue Reading
Deck Commerce Shines as a Leader in Omnichannel Management

Updated Category News Views 199

Deck Commerce Emerges as a Leading Innovator In the competitive landscape of order management systems, Deck Commerce stands out as a beacon of innovation and excellence. Recently recognized by QKS Group's SPARK Matrix™ for 2025, the company has secured its position as both a leader and emerging innovator in the field. This accolade reflects Deck Commerce's dedication to...

Continue Reading
Porsche Penske Motorsport Celebrates Historic Victory

Updated Category News Views 343

Porsche Penske Motorsport Celebrates Historic Victory Porsche Penske Motorsport has achieved remarkable success at the prestigious 24 Hours of Daytona, clinching its second consecutive win. As the race unfolded, the familiar faces of Felipe Nasr, Nick Tandy, and Laurens Vanthoor led the No. 7 Porsche 963 to victory, marking a milestone as Porsche secured its 20th overall...

Continue Reading